Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07405554 · ClinicalTrials.gov registry record · Phase 2
Zinc Supplementation With Botulinum Toxin for Overactive Bladder
A Phase 2 study of Overactive Bladder (OAB), sponsored by Endeavor Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT07405554: Recruiting Phase 2 study of Overactive Bladder (OAB), sponsored by Endeavor Health.
NCT07405554 is a Phase 2 study of Overactive Bladder (OAB) that is actively recruiting participants, run by Endeavor Health. The registered enrollment target is 72 participants, below the 282-participant average among 7 other Overactive Bladder (OAB) trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07405554, a Phase 2 study of Overactive Bladder (OAB), is actively recruiting participants, sponsored by Endeavor Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized, double-blind, placebo-controlled trial evaluates whether oral zinc plus phytase supplementation modifies clinical response to intradetrusor botulinum toxin injection in patients with overactive bladder. Participants will receive either zinc plus phytase supplementation or matching placebo for five days prior to intradetrusor botulinum toxin injection. Participants will be followed for six months after treatment to assess need for repeat botulinum toxin injection, urinary symptoms, and patient-reported outcomes related to overactive bladder.
Primary Outcome
Number of patients who subjectively report a need for repeat intradetrusor botulinum toxin injection at 6 months following the index injection.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Zinc Citrate Oral Capsule
Study Locations (1)
Illinois
- Endeavor Health - Skokie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2026-02-26 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT07405554 shows while recruiting
NCT07405554 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 282-participant average among 7 other Overactive Bladder (OAB) trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Overactive Bladder (OAB) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07405554 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT07405554 about?
NCT07405554 is a clinical study titled "Zinc Supplementation With Botulinum Toxin for Overactive Bladder". This randomized, double-blind, placebo-controlled trial evaluates whether oral zinc plus phytase supplementation modifies clinical response to intradetrusor botulinum toxin injection in patients with overactive bladder. Participants will receive either zinc plus phytase supplementation or matching p...
What is the current status of trial NCT07405554?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2026-02-26. Estimated completion is 2026-12.
What conditions does trial NCT07405554 study?
This clinical trial studies the following conditions: Overactive Bladder (OAB).
What interventions are being tested in trial NCT07405554?
The interventions under investigation include: Placebo (DRUG), Zinc Citrate Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT07405554?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07405554 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder (OAB)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Pumpkin Seed Oil Extract Supplementation on Bladder Function
RECRUITING · NA
-
PMCF Study of the Axonics SNM System Model 5101 (R20)
RECRUITING · NA
-
Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections
RECRUITING
-
Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women
RECRUITING · NA
-
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
RECRUITING · NA
-
APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI